Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy

Baseline inflammatory biomarkers identify subgroups of HIV-infected African children with differing responses to antiretroviral therapy

Background: Identifying determinants of morbidity and mortality may help target future interventions for HIV-infected children. <br/>Methods: CD4, HIV-1 viral load (VL) and biomarkers (CRP/TNF-/IL-6/sCD14/IL-7) were measured at ART initiation in the ARROW trial (case-cohort design). Cases wer...

Full description

Bibliographic Details
Main Authors:	Prendergast, A, Szubert, A, Berejena, C, Pimundu, G, Pala, P, Shonhai, A, Musiime, V, Bwakura-Dangarembizi, M, Poulsom, H, Hunter, P, Musoke, P, Kihembo, M, Munderi, P, Gibb, D, Spyer, M, Walker, A, Klein, N
Format:	Journal article
Published:	Oxford University Press 2016

Similar Items

The impact of viraemia on inflammatory biomarkers and CD4 cell subpopulations in HIV-infected children in sub-Saharan Africa
by: Prendergast, AJ, et al.
Published: (2021)

Inflammatory biomarkers in HIV-infected children hospitalized for severe malnutrition in Uganda and Zimbabwe
by: Prendergast, A, et al.
Published: (2019)

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.
by: Szubert, A, et al.
Published: (2015)

Virological response and resistance among HIV-infected children receiving long-term antiretroviral therapy without virological monitoring in Uganda and Zimbabwe: Observational analyses within the randomised ARROW trial
by: Szubert, A, et al.
Published: (2017)

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.
by: Crook, A, et al.
Published: (2016)

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
by: Musoke, P, et al.
Published: (2015)

Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
by: Bwakura-Dangarembizi, M, et al.
Published: (2015)

Marginal structural models for repeated measures where intercept and slope are correlated: an application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy
by: Farmer, R, et al.
Published: (2020)

Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.
by: Kekitiinwa, A, et al.
Published: (2013)

A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.
by: Bwakura-Dangarembizi, M, et al.
Published: (2014)

Enhanced prophylaxis with antiretroviral therapy for advanced HIV in Africa
by: Hakim, J, et al.
Published: (2017)

Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation
by: Bourke, CD, et al.
Published: (2019)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy.
by: Ruth E Farmer, et al.
Published: (2020-01-01)

Opportunities for improving the efficiency of paediatric HIV treatment programmes.
by: Revill, P, et al.
Published: (2015)

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
by: Prendergast, A, et al.
Published: (2016)

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
by: Riitho, V, et al.
Published: (2024)

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial
by: Mallewa, J, et al.
Published: (2018)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial
by: Kityo, C, et al.
Published: (2018)

Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.
by: Fillekes, Q, et al.
Published: (2014)

Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.
by: Walker, A, et al.
Published: (2012)

Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa
by: Victor Riitho, et al.
Published: (2024-06-01)

Causes and timing of mortality and morbidity among late presenters starting antiretroviral therapy in the REALITY trial
by: Post, F, et al.
Published: (2018)

Virologic response to first-line efavirenz- or nevirapine-based anti-retroviral therapy in HIV-infected African children
by: Kekitiinwa, A, et al.
Published: (2017)

The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa
by: Walker, SM, et al.
Published: (2020)

Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study.
by: Picat, M, et al.
Published: (2013)

Approaches towards avoiding lifelong antiretroviral therapy in paediatric HIV infection.
by: Goulder, P, et al.
Published: (2011)

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
by: Reid, A, et al.
Published: (2008)

Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial.
by: Cissy Kityo, et al.
Published: (2018-12-01)

Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.
by: Muyingo, S, et al.
Published: (2008)

Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
by: Stöhr, W, et al.
Published: (2011)

Impact of second-line antiretroviral regimens on lipid profiles in an African setting: the DART trial sub-study.
by: Gomo, Z, et al.
Published: (2014)

Bone mineral density among children living with HIV failing first-line anti-retroviral therapy in Uganda: A sub-study of the CHAPAS-4 trial.
by: Eva Natukunda, et al.
Published: (2023-01-01)

Inflammation: the driver of poor outcomes among children with severe acute malnutrition?
by: Sturgeon, JP, et al.
Published: (2023)

DART and laboratory monitoring of HIV treatment Reply
by: Walker, A, et al.
Published: (2010)

Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
by: Gibb, D, et al.
Published: (2012)

Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.
by: Walker, A, et al.
Published: (2010)

Caring for children with SAM: Intersectional stories of shame, blame and stigmatisation in Zimbabwe, Zambia and Kenya
by: Tim Brown, et al.
Published: (2025-12-01)

Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
by: Mugyenyi, P, et al.
Published: (2010)

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min
by: Ross, LL, et al.
Published: (2019)